ClinicalTrials.gg
CompletedNCT07211607Updated May 8, 2026

I.V. Selonabant in Healthy Adult Subjects

A Phase 1 interventional study of selonabant and placebo in Healthy Volunteers, sponsored by Anebulo Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Anebulo Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, and PK of single IV doses of selonabant in healthy adult participants between 18 and 25 years of age. The study will enroll up to 5 sequential cohorts of 8 subjects (6 active, 2 placebo) for a total of up to 40 subjects. The starting dose of selonabant will be 1 mg and the planned doses for subsequent cohorts are 2, 5, 10, and 20 mg. The study is supported by a collaborative U01 grant from NIDA.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Anebulo Pharmaceuticals is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. The subject is male or female 18 to 30 years of age, inclusive.
  2. The subject has a of 18 to 30 kg/m2, inclusive, and with a minimum weight of 50 kg and maximum weight of 110 kg.
  3. The subject has no medical history and no clinically significant findings in vital sign measurements, 12-lead results, and physical examination findings at screening that would pose a risk in study participation, as determined by the investigator. The subject has no clinical laboratory test results outside the reference range that remain out of range after up to 2 repeat tests within the screening window.
  4. The female subjects must be surgically sterile (ie, hysterectomy and/or oophorectomy) or agree to use a highly effective method of in addition to a secondary barrier method of contraception during the study and for at least 110 days (90 days plus 5 selonabant half-lives, assuming a half-life of 80 hours) after dosing with study treatment.

Key Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. The subject has used any prescription (excluding hormonal birth control) or over the counter medications within 14 days or less than 5 half-lives (whichever is longer) of screening and for the entire duration of the study. Exceptions will only be made upon the investigator's decision and discussion with the Sponsor.
  3. The subject has used any vitamin, mineral, herbal, or dietary supplements within 14 days or less than 5 half-lives (whichever is longer) of screening and for the entire duration of the study. Exceptions will only be made upon the investigator's decision and discussion with the Sponsor.
  4. The subject has used any cannabis products within 14 days of study drug administration.
  5. The subject uses any anti-anxiety, anti-depressant, anti-psychotic, anti-epileptic, or anti-migraine medication.
  6. The subject has a positive urine drug screen result for drugs of abuse at screening or check-in.
  7. The subject has a history of alcohol abuse or drug addiction within the last year
  8. The subject's alcohol urine test at screening or check-in was positive. Alcohol will not be allowed for at least 24 hours before screening or check-in until discharge.
  9. The subject has used nicotine- or tobacco-containing products in the last 3 months. Smoking and nicotine use will not be allowed during the study.
  10. The subject has used any caffeine-containing food or drink (eg, tea, coffee, cola, chocolate) or 'energy' drinks within 24 hours before study admission. Caffeine containing food and drink will not be allowed from at least 24 hours before screening or check-in until discharge.
  11. The subject has received a diagnosis (or tests positive at screening) for or .
  12. The subject has a history of , or tests positive for HIV, or has evidence of active tuberculosis (history and/or radiology findings) at screening.
  13. The subject has a medical history of impaired cardiac function or clinically significant cardiac disease
  14. The subject has an estimated of \<90 mL/min/1.73 m2, based on the CKD-EPI equation.
  15. The subject has any abnormal, out-of-range screening laboratory values that remain outside laboratory-defined limits after up to 2 repeat tests within the screening window.
  16. The subject has SBP >130 or \<90 mm Hg, and DBP >95 or \<50 mm Hg at screening or check-in. If a subject fails to meet SBP and/or DBP criteria, up to 2 repeat measurements, one via automated device and one via manual reading, may be completed after the subject has remained in the seated position for 5 minutes between readings, at the discretion of the investigator. For those subjects who have a repeat blood pressure measurement, the repeat value will be used to determine eligibility.
  17. The subject had a loss of blood or donated blood or blood products >500 mL within 4 months prior to screening or has the intention to donate blood or blood products during the study.
  18. The subject has a baseline coagulation test result outside the normal range for the clinical site.
  19. The subject has a history of arterial or venous thrombosis or a family history of a coagulopathy.
  20. The subject has any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as a history of seizures (excluding febrile convulsions below 3 years of age).
  21. The subject has a current psychiatric disorder (including depression), schizophrenia, bipolar disorders, eating disorders, personality disorders, post-traumatic stress disorders, anxiety disorders (including panic, obsessive-compulsive disorders, and phobias), a history of depression or suicidal ideation, or a history of suicide attempt.
  22. The subject has a current or history of neurological disease, including but not limited to, seizure disorder, cerebrovascular disease, intractable headache syndromes (e.g. intractable migraines, history of eclampsia, cluster headaches), multiple sclerosis, ataxias, and extrapyramidal disorders.
  23. The subject has a positive test for SARS-CoV-2.
  24. The subject has a history of serious reaction to a known ingredient of selonabant or .
  25. The subject has received study drug (selonabant) in any study or received any other investigational study drug in any other study within 30 days of dosing or 5 half lives, whichever is longer.
  26. The subject has difficult venous access or a history of infusion site reactions, including local tissue reactions, hyperpyrexia, or any related reactions.
  27. The subject has intercurrent illness that is either life threatening or of clinical significance such that it might limit compliance with study requirements, or in the investigator's assessment would place the subject at an unacceptable risk for study participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Experimental Cohort 1

    Single intravenous dose of 1 mg of selonabant or placebo

    Drug: selonabant · Drug: placebo

  • Experimental
    Experimental Cohort 2

    Single intravenous dose of 2 mg of selonabant or placebo

    Drug: selonabant · Drug: placebo

  • Experimental
    Experimental Cohort 3

    Single intravenous dose of 5 mg of selonabant or placebo

    Drug: selonabant · Drug: placebo

  • Experimental
    Experimental Cohort 4

    Single intravenous dose of 10 mg of selonabant or placebo

    Drug: selonabant · Drug: placebo

  • Experimental
    Experimental Cohort 5

    Single intravenous dose of 20 mg of selonabant or placebo

    Drug: selonabant · Drug: placebo

Interventions

  • Intravenous infusion of selonabant

    Also known as: ANEB-001

  • Drugplacebo

    Placebo infusion which looks the same as the selonabant infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Time frame: 28 days

  2. Number of Participants with Clinically Significant Laboratory Test Results

    Time frame: 28 days

  3. Number of Participants with Clinically Significant Vital Signs Values

    Time frame: 28 days

  4. Number of Participants with Clinically Significant Abnormal ECG Findings

    Time frame: 28 days

  5. Number of Participants with Clinically Significant Abnormal Physical Exam Findings

    Time frame: 28 days

  6. Change from Baseline in Beck Depression Inventory (BDI)

    The minimum possible Beck Depression Inventory (BDI) score is 0, and the maximum score is 63. This score is determined by summing the ratings from the 21 questions, with each question scoring from 0 to 3, indicating the severity of depressive symptoms over the past two weeks. Lower score means less depression

    Time frame: 28 days

  7. Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) does not have a single minimum or maximum score, as it is not a traditional cumulative-score test. Instead, it uses a series of "yes" or "no" questions to place an individual into distinct categories of risk based on their specific responses. Lower score means less suicidal ideation.

    Time frame: 28 days

  8. Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration

    Time frame: 28 days

  9. Terminal Elimination Phase Half-life (T1/2)

    Time frame: 28 days

  10. Maximum Observed Concentration (Cmax)

    Time frame: 28 days

  11. Pharmacokinetic Clearance (CL)

    Pharmacokinetic clearance (\\(CL\\)) is a quantitative measure of how efficiently the body removes a drug from the bloodstream. It is defined as the volume of plasma from which a drug is completely and irreversibly removed per unit of time and is typically expressed in units like milliliters per minute (mL/min) or liters per hour (L/h).

    Time frame: 28 days

07

Study locations

1 site
  • PPD Austin Clinical Research Unit
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in May 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 8, 2025
StartActual
Sep 22, 2025
Primary completionActual
May 6, 2026
CompletionActual
May 6, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211607
Lead sponsor
Anebulo Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Sep 22, 2025
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
May 8, 2026

Study contacts

Sean Gilbey, MD
principal investigator · PPD Austin Clinical Research Unit
Rebecca Wood-Horrall, MD
study chair · PPD Austin Clinical Research Unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selonabant

Start the discussion